Hugues deLavallade

INTRODUCTION The introduction of post-transplant cyclophosphamide (PTCy) enabled T replete bone marrow (BM) haploidentical transplants with low rates of both acute and chronic graft-versus-host disease (GVHD).1 The retrospective data for PTCy with peripheral blood stem cell (PBSC) showed acute grade 2 GVHD was higher (53%) but grade 3–4 was 8% and the 2-year cumulative incidence (CuI) of chronic GVHD 18% was similar to the use of BM grafts.2 A center for international blood and marrow...